Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. by Daly, Celine Costello et al.
JOURNAL OF CLINICAL MICROBIOLOGY,
0095-1137/97/$04.0010
Nov. 1997, p. 2985–2988 Vol. 35, No. 11
Copyright © 1997, American Society for Microbiology
Development of an Antimicrobial Susceptibility Surveillance
System for Neisseria gonorrhoeae in Malawi:
Comparison of Methods
CELINE COSTELLO DALY,1 IRVING HOFFMAN,2* MARCIA HOBBS,2 MARTIN MAIDA,3
DICK ZIMBA,3 RACHAEL DAVIS,2 G. MUGHOGHO,3 AND MYRON S. COHEN2
John Snow, Inc., Boston, Massachusetts1; Department of Medicine, Division of Infectious Diseases,
University of North Carolina, Chapel Hill, North Carolina2; and Lilongwe Central Hospital, Lilongwe, Malawi3
Received 8 May 1997/Returned for modification 10 July 1997/Accepted 19 August 1997
Susceptibility of Neisseria gonorrhoeae to gentamicin, the primary treatment for gonorrhea in Malawi since
1993, was determined by using agar dilution MICs, E-test MICs, disc diffusion, and clinical cure rate. Agar
dilution MICs were slightly higher in 1996 than in 1993 isolates, with a concomitant drop in the clinical cure
rate. E-test MICs were substantially lower than agar dilution determinations, with only 77.4% within 1 log2
concentration.
Rates of gonorrhea infection are high worldwide, especially
in developing countries (21). In Malawi, cervical infection with
Neisseria gonorrhoeae was found in 5% of urban antenatal
women, comparable to infection rates in low-risk populations
in other countries in the region (6, 9). Gonococcal infections
facilitate the transmission of human immunodeficiency virus
(10), and increased shedding of human immunodeficiency vi-
rus type 1 in semen of infected men has been demonstrated
(3).
In Malawi, penicillin was the drug of choice for the treat-
ment of gonorrhea until clinical efficacy studies and agar dilu-
tion MIC determinations carried out by the AIDS Control and
Prevention Project from 1991 to 1993 found high-level gono-
coccal resistance to penicillin, tetracycline, and streptomycin
(12). Based on clinical efficacy, MIC data, and cost, gentamicin
(240-mg single intramuscular dose) was adopted in 1993 as the
treatment of choice for gonorrhea in Malawi (13, 14). Single-
dose gentamicin has been shown to be effective in the treat-
ment of gonococcal urethritis and cervical infection (2, 7, 8, 15,
17, 19). Since early 1994, gentamicin has been widely used in
the syndromic treatment of all urethral discharge but no stud-
ies of its continued efficacy have been performed.
Monitoring of the antimicrobial susceptibility of N. gonor-
rhoeae in developing countries is essential in an environment of
rapidly changing resistance patterns (5, 11). However, surveil-
lance systems involving clinical efficacy studies and agar dilu-
tion methods for determining MICs are time-consuming and
expensive. In addition, the laboratory capability for agar dilu-
tion testing is limited to reference laboratories in developed
countries. While these methods may be feasible for donor-
funded special studies, they are not sustainable for long-term
monitoring.
The objectives of the present study were to determine the
clinical efficacy of gentamicin in the treatment of N. gonor-
rhoeae 2 years after the onset of its widespread use and to
evaluate the possible roles of disc diffusion and the E test in the
development of a surveillance system in Malawi for monitoring
the susceptibility of N. gonorrhoeae to gentamicin.
(A preliminary report of this work was presented at the 12th
Meeting of the International Society of Sexually Transmitted
Diseases Research, Seville, Spain, 20 October 1997.)
Study population. This study was conducted at Lilongwe
Central Hospital in Lilongwe, Malawi, between January and
March 1996. Also presented are data from 198 male patients at
Queen Elizabeth Central Hospital, Blantyre, Malawi, between
September 1992 and March 1993 as part of a larger study to
determine effective urethritis therapy (13).
Clinical specimens. After administration of a questionnaire
and a physical examination, urethral swab specimens were ob-
tained for microscopy of the Gram-stained smear and for cul-
ture of N. gonorrhoeae. After giving informed consent, 206
consecutive men presenting to the sexually transmitted disease
clinic in Lilongwe with complaints of urethral discharge were
enrolled. Gonorrhea was presumptively diagnosed by the pres-
ence of gram-negative intracellular diplococci (GNID) on the
first visit and confirmed by culture. Subjects were asked to
return in 7 days, and a follow-up urethral swab specimen was
taken for repeat Gram stain and culture. A stipend was given
for return visits.
Urethral specimens were directly inoculated onto chocolate
agar (GC agar base, bovine hemoglobin, IsoVitaleX) and im-
mediately placed in candle extinction jars. Cultures were incu-
bated at 35°C and inspected for growth indicative of N. gon-
orrhoeae after 24 and 48 h. A Gram stain was performed on
oxidase-positive colonies with characteristic morphology. Iso-
lates were subcultured for 24 h on chocolate agar and then
used for E-test and disc diffusion analysis. Each isolate was
placed in transport medium and stored in liquid nitrogen until
shipment on dry ice to the University of North Carolina for
MIC determination by the agar dilution method.
All patients presenting with urethral discharge had urethri-
tis, defined as the presence of five or more leukocytes per
high-power field on Gram stain, and 51.9% (107 of 206) had
cultures positive for N. gonorrhoeae. The mean reported dura-
tion of urethral discharge was 14 days (median, 7 days; range,
0 to 360 days). Although 51.5% reported treatment with an
antibiotic in the previous 2 weeks, only one subject had re-
ceived treatment effective against gonorrhea (gentamicin at an
unknown dosage).
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Treatment and clinical efficacy of gentamicin. At the initial
visit, men with urethritis and GNID on Gram stains were
treated with gentamicin (240-mg single intramuscular dose).
Failure of treatment for gonorrhea was defined as persistent
GNID on Gram stain after 1 week or a positive N. gonorrhoeae
culture. Men with persistent urethritis after 1 week were
treated with ciprofloxacin (500-mg single oral dose) and
azithromycin (1-g single oral dose).
Of the 107 patients with a positive gonorrhea culture on the
first visit, 90 (84%) returned for a follow-up culture. Of the
returning patients, five were excluded from the analysis of
clinical efficacy: four received azithromycin on the first treat-
ment visit in addition to gentamicin, and for one with a positive
gonococcal culture on the second visit, the gentamicin MIC
was substantially lower than on the initial visit (8 versus 32
mg/ml) and was considered to be reinfected, despite denying
having had sexual intercourse between cultures, as did all sub-
jects with persistent gonorrhea after treatment. The clinical
cure rate for gentamicin treatment of gonorrhea was 91.8%
(n 5 85; 95% confidence interval, 83.8 to 96.6%) in 1996
compared to 95% (n 5 40; 95% confidence interval, 83.8 to
99.4%) in 1993 (13). Although the treatment failure rate was
slightly increased in 1996, the difference was not statistically
significant.
Microbial susceptibility testing. We compared disc diffusion
and E-test gentamicin susceptibility determinations for N. gon-
orrhoeae with the “gold standard” for MICs, the agar dilution
technique. Both disc diffusion and the E test are widely avail-
able, low-technology methods requiring only the ability to
carry out N. gonorrhoeae cultures on agar plates. The E test has
proven useful in measuring gonococcal susceptibility to a va-
riety of antibiotics (4, 18, 20, 22); however, none of these
studies was performed in a developing country field laboratory
setting.
For disc diffusion and E-test susceptibility determinations,
inocula were prepared with N. gonorrhoeae isolates suspended
in saline to a turbidity equivalent by inspection with the naked
eye to a 0.5 McFarland standard. Chocolate agar plates were
streaked over the entire surface with a wire loop to deliver the
bacterial suspension. A 10-mg gentamicin disc (BBL Sensi Disc
Antimicrobial Susceptibility test discs; Becton Dickinson) and
a gentamicin E-test strip (AB Biodisk North America, Inc.,
Piscataway, N.J.) containing an exponential antibiotic gradient
on one side and an MIC reading scale marked on the other
were firmly placed on the plate. Plates were incubated for 24 h
at 35°C in candle extinction jars.
The diameter of the growth inhibition zone surrounding the
gentamicin disc was read to the nearest millimeter. The diam-
eters of N. gonorrhoeae inhibition zones by disc diffusion
ranged from 15 to 22 mm (data not shown). There were no
significant differences in the diameters of inhibition zones at
different MICs by agar dilution (Pearson’s chi square, 17.0;
P 5 0.95).
E-test MICs were determined by reading the value at the
point of intersection between the edge of the zone of growth
inhibition and the E-test strip. Intermediate E-test values fall-
ing between standard agar dilutions were rounded up to the
next highest twofold dilution, as suggested by the manufac-
turer. An Escherichia coli control strain (ATCC 25922) with a
standard gentamicin E-test range of 0.25 to 1.00 mg/ml and a
10-mg disc diameter of 19 to 26 mm was used as a control
before and then monthly during the 3-month trial. Disc diffu-
sion and E-test values for the E. coli control strain consistently
fell within the standard ranges.
MIC determination by agar dilution followed the current
Centers for Disease Control and Prevention guidelines for the
National Gonococcal Isolate Surveillance Project (U.S. Public
Health Service, Center for Infectious Diseases, Division of
Sexually Transmitted Diseases Laboratory Research, Atlanta,
Ga.). Susceptibilities were determined on GC agar base me-
dium supplemented with 1% IsoVitaleX inoculated with 104
CFU of each strain. Gentamicin and other antibiotics were
serially diluted into a series of plates for concentrations of
0.001, 0.015, 0.06, and 0.12 mg/ml and doubling concentrations
from 0.5 to 256 mg/ml. The agar dilution MIC was defined as
the lowest concentration of antibiotic that completely inhibited
growth of the inoculum. MICs of penicillin and tetracycline for
N. gonorrhoeae showed that .83% of the isolates were resis-
tant to these antibiotics (data not shown). Isolates were uni-
formly sensitive (MICs, ,0.125 mg/ml) to ciprofloxacin (n 5
44), cefixime (n 5 63), and ofloxacin (n 5 63).
Agar dilution MICs of gentamicin are summarized in Table
1. The comparison of gentamicin MICs from 1993 and 1996
revealed a statistically significant difference by the Wilcoxon
rank-sum test (P , 0.01), with the proportion of highly sus-
ceptible isolates falling from 17.2% in 1993 to 9.5% in 1996.
However, the median MIC (8 mg/ml) was unchanged from
1993 to 1996 and the majority of isolates remained in the
moderately susceptible category.
In 1993, 40 of the 198 isolates were treated with gentamicin.
There were two treatment failures, for both of which the MIC
was $16 mg/ml. Of those treated with gentamicin, the MICs for
eight isolates were $16 mg/ml. Three were lost to follow-up; of
the five returning, two were treatment failures. In 1996, the
MICs for four of the seven patients experiencing treatment
failure with a single dose of gentamicin ranged from 4 to 16
mg/ml (one was 4 mg/ml, two were 8 mg/ml, and one was 16
mg/ml).
There are no standardized interpretative criteria for genta-
micin MICs in the treatment of N. gonorrhoeae. By the Na-
tional Committee for Clinical Laboratory Standards criteria
for aerobic bacteria other than N. gonorrhoeae, Streptococcus
pneumoniae, and Haemophilus species (16), three of the four
treatment failures in 1996 and both of the failures in 1993 were
in the category of moderate susceptibility. It is interesting that
of the two isolates for which the MIC was 32 mg/ml in 1996,
one responded to gentamicin treatment and one patient failed
gentamicin therapy but when he returned for a second visit, the
MIC was 8 mg/ml, suggesting reinfection.
Comparison of MICs determined by agar dilution and the E
test. Table 2 shows gentamicin MICs for N. gonorrhoeae iso-
lates determined by agar dilution assay and the E test. Consis-
tent with other reports, the E test gave lower MICs than did
the agar dilution assay. Other studies have reported agree-




No. of isolates for which agar dilution MIC
(mg/ml) was: No. of
isolates
0.5 1 2 4 8 16 32
1993 2b 1b 2b 29b 119c 44c 1d 198
1996 2e 4e 32f 23f 2g 63
a Based on interpretative criteria for aerobic bacteria other than S. pneu-
moniae, Haemophilus spp., and N. gonorrhoeae (16).
b Percentage of high-susceptibility isolates, 17.2%.
c Percentage of moderate-susceptibility isolates, 82.3%.
d Percentage of low-susceptibility isolates, 0.5%.
e Percentage of high-susceptibility isolates, 9.5%.
f Percentage of moderate-susceptibility isolates, 87.3%.
g Percentage of low-susceptibility isolates, 3.2%.
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ments of 76 to 98%, depending on the study and on the anti-
biotic used (1, 4, 18, 20, 22). In studies reporting the lowest
agreement (4, 20), there were no differences in the suscepti-
bility category of the isolates between methods. We found a
large discrepancy in the susceptibility category (60.4% highly
susceptible by the E test versus 9.5% by the agar dilution
assay). However, this observation is limited by the difficulty in
assessing gentamicin susceptibility categories. For 77% of the
1996 N. gonorrhoeae isolates from Malawi, the MICs were
within 1 dilution on both tests.
This low rate of agreement between the E test and agar
dilution may be at least partially attributed to the performance
of the E test in a field setting. Previous comparisons were
performed in the same reference laboratory. In a field labora-
tory, the difficulties in achieving a consistent inoculum density
for the E test may have contributed to the relatively low con-
cordance between the two tests, since the 0.5 McFarland tur-
bidity of the inoculum was determined by the naked eye
against the ever-changing natural light from a window. In ad-
dition, the edges of the inhibition zone on each side of the strip
were often not symmetrical, leaving the interpretation of the
exact MIC to the laboratory technician. The use of a cotton-
tipped swab rather than a wire loop to inoculate plates for the
E test (and disc diffusion) in future trials may provide more
even bacterial growth.
Despite all of the possible difficulties, the MICs for our E.
coli control were consistently within the standard ranges. E.
coli may not be the optimal control for tests using gonococ-
cal suspensions, since the suspension characteristics of the
organisms are different. However, the laboratory in Lilongwe,
Malawi, was not equipped to maintain long-term cultures of an
N. gonorrhoeae reference strain, and a control gentamicin sus-
ceptibility range has not been established for this organism.
The E. coli culture was easily maintained in the field labora-
tory, and our achievement of consistent E-test and disc diffu-
sion control MICs for this strain validates the drug delivery
devices and agar plates used in this study.
Although disc diffusion is the most widely available and least
expensive method studied, it was not helpful in determining
the efficacy of gentamicin since there was very little difference
in the range of disc diameters at different MICs determined by
agar dilution. Gentamicin discs containing different drug con-
centrations may be more discriminatory between susceptible
and resistant N. gonorrhoeae isolates. This possibility remains
to be tested.
We found no single method of antimicrobial susceptibility
testing that was sufficient when used alone for the surveillance
of gonococcal susceptibility to gentamicin. The clinical efficacy
data showed a trend toward increasing resistance to gentami-
cin, with cure rates of 95% in 1993 and 92% in 1996, but the
difference was not statistically significant. As a method of mon-
itoring susceptibility patterns, clinical efficacy testing is time-
consuming and is biased by losses to follow-up. The high fol-
low-up rate in this study was largely due to monetary stipends
and adequate full-time staff hired specifically for the study,
both of which would not be available for routine monitoring
carried out by the government of Malawi. However, the bias
due to loss to follow-up would be in the direction of an in-
creased level of resistance since those with a poor response to
treatment would be more likely to return to the clinic. The
effect of bias due to reinfection between visits would also
overestimate the degree of reinfection in clinical studies.
There was a general trend toward higher gentamicin MICs
as determined by the agar dilution assay for 1996 N. gonor-
rhoeae isolates than for 1993 isolates. In addition, the percent-
age of isolates with high susceptibility (MIC, #4 mg/ml) de-
creased from 17.2 to 9.5% of the total isolates. This parallels
the findings of the clinical study. Almost all of the treatment
failures reported here were in the category of moderate sus-
ceptibility, but the two isolates in the low-susceptibility cate-
gory responded to treatment with gentamicin. Since gentami-
cin is still effective for the treatment of gonorrhea in Malawi,
we were not able to establish an MIC that clearly showed
resistance.
As resistance to gentamicin increases, adoption of second-
line antibiotics for the treatment of N. gonorrhoeae must be
considered. There were no signs of resistance to the other
antibiotics tested in this study. All isolates continued to be fully
sensitive to ciprofloxacin, ofloxacin, and cefixime, largely due
to their relative lack of availability in Malawi. However, the
large price differential between gentamicin and the next line of
antibiotics makes the decision to change treatment guidelines
to a more effective drug a difficult one in the setting of an
overall drug shortage.
There is a need for ongoing antibiotic susceptibility moni-
toring systems in resource-poor countries. While the agar di-
lution assay remains the method of choice for MIC determi-
nation in reference laboratories in developed countries, the E
test could be operational within a developing country labora-
tory setting. However, the poor performance of the E test in
this study suggests that its role is limited in the monitoring of
antibiotic efficacy for gonorrhea under field conditions. It is
possible that the E test would be a valuable tool for following
trends in MICs, especially when used in combination with a
clinical cure study. Further research under field conditions in
developing countries using different antibiotics is required be-
fore the E test can be adopted as the sole tool for the moni-
toring of N. gonorrhoeae antibiotic susceptibility.
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